Prothena stock analysis
Prothena (0Y3M) Share Price & Analysis
0Y3M Stock Chart & Stats
- Day’s Range
- $7.99 - $8.33
- 52-Week Range
- $7.82 - $11.66
- Previous Close
- $8.26
- Volume
- N/A
- Average Volume (3M)
- 1,274
- Market Cap
- $419.01M
- Enterprise Value
- $165.93M
- Total Cash (Recent Filing)
- $271.37M
- Total Debt (Recent Filing)
- $6.26M
- Price to Earnings (P/E)
- ―
- Beta
- 0.25
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- 0.02
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Partnered Phase 3 Pipeline
Two partnered programs have advanced to Phase 3, providing Prothena with late-stage clinical assets and validation from major pharmaceutical collaborators. Successful development could create durable milestone and royalty opportunities while reducing the burden of independently commercializing the products.
Low Financial Leverage
Very low leverage limits interest and refinancing pressure, giving Prothena greater flexibility to fund research and withstand development setbacks. This balance-sheet position is a meaningful buffer for a clinical-stage company whose cash flows depend on partnerships and milestone timing.
Strategic Partnership Economics
The partnership model has already produced substantial non-product funding and retains significant contingent upside from development, regulatory, and commercial milestones. This broadens Prothena’s potential revenue base beyond its current operations and leverages partners’ clinical and commercial capabilities.
Bears Say
Persistent Cash Burn
Negative and deteriorating cash generation means Prothena remains dependent on its cash reserves, partner payments, or future financing to sustain development. Continued operating burn can reduce strategic flexibility and increase dilution or funding pressure if milestones arrive later than expected.
Unprofitable And Volatile Revenue
The company has not converted its scientific pipeline into consistent profitability, and recent revenue contraction highlights the event-dependent nature of collaboration income. Ongoing R&D and SG&A losses could persist until partnered programs generate larger milestones or commercial royalties.
PRX019 License Termination
Termination of PRX019 removes a substantial potential revenue stream and demonstrates that partnered assets can be discontinued despite progressing through early clinical development. The setback narrows the collaboration portfolio and increases reliance on the remaining programs to deliver future value.
Prothena News
0Y3M FAQ
What was Prothena’s price range in the past 12 months?
What is Prothena’s market cap?
When is Prothena’s upcoming earnings report date?
How were Prothena’s earnings last quarter?
Is Prothena overvalued?
Does Prothena pay dividends?
What is Prothena’s EPS estimate?
How many shares outstanding does Prothena have?
What happened to Prothena’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Prothena?
What is the TipRanks Smart Score and how is it calculated?
Prothena Stock Smart Score
Company Description
Prothena
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gene G. Kinney
- Employees
- 67
- Website
- www.prothena.com
- Address
- 77 Sir John Rogerson’s Quay, Dublin, DU, D02 VK60, IE
Prothena (0Y3M) Earnings & Revenues
0Y3M Earnings Call
Earnings Call SentimentPositive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.
View all GB:0Y3M earnings summaries0Y3M Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |












